NCT06372821View on ClinicalTrials.gov

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Alzheimer DiseaseAutosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
Interventions
DRUG

NIO752

Antisense oligonucleotide

OTHER

Placebo

Saline

Trial Locations (1)

NW1 2PG

RECRUITING

University College London Hospitals NHS Foundation Trust, London

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

collaborator

University of Washington

OTHER

collaborator

Alzheimer's Association

OTHER

collaborator

Sigrid Rausing Trust

OTHER

lead

University College, London

OTHER

NCT06372821 - A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK | Biotech Hunter | Biotech Hunter